ImmunityBio, Inc.

Immunitybio, Inc.

Biotechnology • Healthcare • San Diego, CA, United States • IBRX (NMS)

ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.

844 696 5235 3530 John Hopkins Court, San Diego, CA 92121, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Is ImmunityBio Inc. (IBRX) The Best US Stock To Buy Under $20? - Yahoo Finance
Yahoo Finance • Nov 30
A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs (NASDAQ:IBRX) - Seeking Alpha
Seeking Alpha • Dec 3
ImmunityBio, Inc. (NASDAQ:IBRX) Short Interest Up 23.1% in December - MarketBeat
MarketBeat • Dec 31
A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know - The Motley Fool
The Motley Fool • Nov 19
Meet the cancer doctor named among 2025’s 100 most influential worldwide - Stock Titan
Stock Titan • Dec 29

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has ImmunityBio, Inc. had layoffs?
No layoff events have been recorded for ImmunityBio, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does ImmunityBio, Inc. have?
ImmunityBio, Inc. has approximately 673 employees.
What industry is ImmunityBio, Inc. in?
ImmunityBio, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is ImmunityBio, Inc. a publicly traded company?
Yes, ImmunityBio, Inc. is publicly traded under the ticker symbol IBRX on the NMS. The company has a market capitalization of approximately $2.11 billion.
Where is ImmunityBio, Inc. headquartered?
ImmunityBio, Inc. is headquartered in San Diego, CA, United States at 3530 John Hopkins Court, San Diego, CA 92121, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.